Data Shows Reduction in Incidence, Severity of Autoimmune Myocarditis

CEL-SCI scientists, in collaboration with scientists from the laboratory of Noel Rose at The Johns Hopkins University Department of Pathology, has presented animal data showing that pretreatment and early therapy of Experimental Autoimmune Myocarditis with a compound developed by CEL-SCI resulted in significant reduction in heart enlargement and disease associated histopathological changes.

The compound used to achieve these results was derived from CEL-SCI's patented L.E.A.P.S. (Ligand Epitope Antigen Presentation System) platform technology. This new finding could potentially lead to the development of a treatment for autoimmune myocarditis, a life-threatening heart disease that is characterized by an enlarged and weakened heart.

Myocarditis is a precursor to dilated cardiomyopathy, a condition leading to a form of chronic heart failure characterized by an inflamed heart.